ECRM_1170x120_4-15-17

David Pinto

Drug chains respond to assault on model

Drug chains respond to assault on model

New formats are popping up throughout the chain drug industry, as retailers seek to overcome the sales malaise that has ensnared the industry this year. To recapture lost momentum, chain drug retailers are testing new store sizes, new merchandise assortments, new product locations within stores and new store concepts, sometimes all at once. It’s far

Chain drug retailing is at a turning point

Chain drug retailing is at a turning point

April is here — and still no resolution on the pending acquisition of Rite Aid Corp. by Walgreens Boots Alliance Inc. As time stretches out, this indecision bodes ill for an acquisition that was until recently viewed as an agreement with benefits for both parties. Now, confusion is apparently overtaking certainty — and there is

Drug chains need to regain control of shelf space

Drug chains need to regain control of shelf space

Once upon a time, the basic drug store merchandise mix was a simple affair, a half-dozen major brands in each product category, a handful of popular sizes, a small assortment of line extensions. No longer. Today’s drug store shelves are crammed with both major and supplementary brands. Indeed, sometimes off-brands dominate. Line extensions sometimes dominate.

Fate of WBA-Rite Aid deal hangs in balance

Fate of WBA-Rite Aid deal hangs in balance

The major question in mass retailing this year, as the industry concludes the second month of 2017, is when — and indeed whether — Walgreens Boots Alliance’s acquisition of Rite Aid will be fruitfully concluded. As anyone who really cares knows by now the deadline for finalizing the Walgreens-Rite Aid merger has been extended to

The leaders are there; who will stand out in chain drug?

The leaders are there; who will stand out in chain drug?

Going into the new year, several key personnel questions await answers, foremost among them the age-old problem of determining who, in 2017, will emerge as the most influential senior staffers at America’s drug chains. The determination is made more difficult by the fact that, as of this writing, Walgreens’ acquisition of Rite Aid remains unresolved.

New year to answer key questions in chain drug retailing

New year to answer key questions in chain drug retailing

The new year is finally here. On balance, 2016 was a year best forgotten. Very few events of a positive nature will be remembered. On the other hand, many unsettling moments would best be reviewed at another time — if at all. As 2017 dawns, several important questions remain to be resolved, a few of

Chain drug industry looks ahead at uncertain future

Chain drug industry looks ahead at uncertain future

For chain drug industry people, 2016 will be remembered as a year best forgotten — as much for the uncertainty of the future as for the problems of the past. As November ended and December began, the National Association of Chain Drug Stores brought industry leaders together in New York City for NACDS Week in

Old retailing order gives way to new future

Old retailing order gives way to new future

As the year nears its end, surprises continue to make news in chain drug retailing. Mostly, negative surprises. Earlier this month, CVS downsized its headquarters staff by some 600 employees, stopping for a moment the retailer’s uninterrupted string of good news. Following that announcement, the Woonsocket, R.I.-based drug chain issued a warning that results might

Drug chains’ beauty business in doldrums

Drug chains’ beauty business in doldrums

In chain drug retailing, the most disappointing product category in 2016 has been beauty care. Indeed, the problem with the beauty care category in chain drug stores is, quite simply, the chain drug store’s inability to generate any significant interest in the category. It performs far more credibly in other mass retailing outlets, and it

It’s time for drug chains to shake things up

It’s time for drug chains to shake things up

Two months remain in 2016, and the news out of the chain drug industry remains relatively scanty. Industry gatherings are few and far between — indeed, three months have passed since the NACDS Total Store Expo gathered the industry together in Boston. Against that background, the NACDS year-end meetings, scheduled for New York City following

Chain drug retailing loses a pair of icons

Chain drug retailing loses a pair of icons

The ranks of the chain drug industry’s giants continue to shrink — and, typically of a business that continues to grow, prosper and change, the tendency is to forget to remember what these icons ­accomplished. Last month, two executives who were instrumental in building chain drug retailing passed away. They were radically different, yet remarkably

IFPW examines future of Rx health care

IFPW examines future of Rx health care

The International Federation of Pharmaceutical Wholesalers held its 2016 General Membership Meeting in London in mid-September. No one can blame you for not immediately recognizing IFPW. Though it is a global organization with members representing countries around the world, it touches only peripherally on the retail pharmacy industry. Rather, its immediate concern is the intersection

Industry in lull as it enters crucial holiday season

Industry in lull as it enters crucial holiday season

The all-important Christmas selling season is about to begin. Truth is, the season begins during the run-up to Halloween and runs, virtually non-stop, through December 24. The highlights are the countdown to the day after Thanksgiving, the period immediately following Thanksgiving week and the final days before Christmas Day. Even now, the nation’s drug stores

1 2 3